Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights,...

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Ewing sarcoma is a rare but aggressive bone and soft tissue cancer.
• Targeting key kinases like PDK1 and AurA presents a potential therapeutic strategy.
• Developing dual inhibitors offers a novel approach to overcome resistance mechanisms.

Purpose of the Study:

• To synthesize and characterize novel 2-oxindole-based compounds as dual PDK1-AurA kinase inhibitors.
• To evaluate the in vitro efficacy and safety profile of these novel compounds.
• To explore the structural basis for dual kinase inhibition and guide further drug design.

Main Methods:

• Chemical synthesis of 2-oxindole derivatives.
• In vitro kinase inhibition assays for PDK1 and AurA.
• Cell-based assays including cytotoxicity and ADME-Tox profiling.
• X-ray crystallography and molecular docking studies.

Main Results:

• Several novel 2-oxindole derivatives were synthesized, with compound 12 showing potent nanomolar inhibition against both PDK1 and AurA.
• Compound 12 demonstrated acceptable in vitro ADME-Tox properties across various cancer and healthy cell lines.
• Structural studies elucidated key interactions between compound 12 and the AurA and PDK1 active sites.

Conclusions:

• Novel 2-oxindole derivatives are effective dual PDK1-AurA kinase inhibitors.
• Compound 12 is a promising lead candidate for in vivo studies in Ewing sarcoma.
• These findings support the development of PDK1/AurA dual-target inhibitors for Ewing sarcoma therapy.